Enhanced exhalation of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in patients with COPD exacerbation: A prospective study

Respiration

Volumn 84, Issue 3, 2012, Pages 231-241

  Kwiatkowska, S ^a   Noweta, K ^a   Zieba, M ^c   Nowak, D ^b   Bialasiewicz, P ^b  

^a Ward of Clinical Pneumology ^*  (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c Center of Lung Diseases Treatment and Rehabilitation in Lodz   (Poland)

Author keywords

Chronic obstructive pulmonary disease; Exhaled breath condensate; MMP 9; TIMP 1

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMLODIPINE; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BISOPROLOL; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CEFUROXIME; CIPROFLOXACIN; ENALAPRIL; FLUTICASONE; FORMOTEROL; GELATINASE B; HYDROCHLOROTHIAZIDE; INDAPAMIDE; IPRATROPIUM BROMIDE; LISINOPRIL; METHYLPREDNISOLONE; METOPROLOL; PANTOPRAZOLE; PREDNISONE; RAMIPRIL; SALBUTAMOL; SALMETEROL; TICLOPIDINE; TIOTROPIUM BROMIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRIAMCINOLONE; UNINDEXED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMORBIDITY; CONCENTRATION (PARAMETERS); CONGESTIVE HEART FAILURE; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; EXHALED BREATH CONDENSATE; FEMALE; FORCED EXPIRATORY VOLUME; GASES, FUMES, VAPORS AND RELATED PHENOMENA; GASTRITIS; GOUT; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; SMOKING; SPIROMETRY; SPUTUM; STABLE ANGINA PECTORIS; WHEEZING;

AGED; BIOLOGICAL MARKERS; BREATH TESTS; DISEASE PROGRESSION; EXHALATION; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SPIROMETRY; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84864093850     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000339417     Document Type: Article

References (31)

1. Fabbri LM, Rabe KF: From COPD to chronic systemic inflammatory syndrome? Lancet 2007; 370: 797-799. (Pubitemid 47320803)
2. Schaaf B, Liebau C, Kurowski V, Droemann D, Dalhoff K: Hospital acquired pneumonia with high-risk bacteria is associated with increased pulmonary matrix metalloprotein-ase activity. BMC Pulm Med 2008; 8:12.
3. Shimada A, Koga T, Oshita Y, Hanada M, Nagafuchi Y, Aizawa H: Reduced pulmonary function is associated with enhanced inflammation and tissue inhibitor of metallo-proteinase 1 concentration in the bronchoal-veolar lavage fluid of patients with lung pa-renchymal sarcoidosis. Kurume Med J 2008; 55: 13-17.
4. O'Kane CM, McKeown SW, Perkins GD, Bassford CR, Gao F, Thickett DR, McAuley DF: Salbutamol up-regulates matrix metal-loproteinase-9 in the alveolar space in the acute respiratory distress syndrome. Crit Care Med 2009; 37: 2242-2249.
5. Ilumets H, Rytila PH, Sovijarvi AR, Terva-hartiala T, Myllarniemi M, Sorsa TA, Kin-nula VL: Transient elevation of neutrophil proteinases in induced sputum during COPD exacerbation. Scand J Clin Lab Invest 2008; 68:618-623.
6. Beeh KM, Beier J, Kornmann O, Buhl R: Sputum matrix metalloproteinase-9, tissue inhibitor of metalloprotinease-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. Respir Med 2003; 97:634-639. (Pubitemid 36675664)
7. Stolarek R, Bialasiewicz P, Krol M, Nowak D: Breath analysis of hydrogen peroxide as a diagnostic tool. Clin Chim Acta 2010; 411: 1849-1861.
8. GOLD Executive and Science Commitees: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary (updated 2009). www.gold-copd.org.
9. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J: Standardisation of spirometry. Eur Respir J 2005; 26: 319-338. (Pubitemid 41079078)
10. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555. (Pubitemid 47403272)
11. Szkudlarek U, Maria L, Kasielski M, Kaucka S, Nowak D: Exhaled hydrogen peroxide correlates with the release of reactive oxygen species by blood phagocytes in healthy subjects. Respir Med 2003; 97: 718-725. (Pubitemid 36675677)
12. Mercer PF, Shute JK, Bhowmik A, Donaldson GC, Wedzicha JA, Warner JA: MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbation. Respir Res 2005; 6: 151.
13. Higashimoto Y, Yamagata Y, Iwata T, Okada M, Ishiguchi T, Sato H, Masuda M, Itoh H: Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients. Eur Respir J 2005; 25:885-890. (Pubitemid 40667688)
14. Culpitt SV, Rogers DF, Traves SL, Barnes PJ, Donnelly LE: Sputum matrix metalloprote-ases: comparison between chronic obstructive pulmonary disease and asthma. Respir Med 2005; 99: 703-710. (Pubitemid 40631296)
15. Xin XF, Zhao M, Li ZL, Song Y, Shi Y: Metal-loproteinase-9/tissue inhibitor of metallo-proteinase-1 in induced sputum in patients with asthma and chronic obstructive pulmonary disease and their relationship to airway inflammation and airflow limitation (in Chinese). Zhonghua Jie He He Hu Xi Za Zhi 2007; 30: 192-196.
16. Cataldo D, Munaut C, Noel A, Frankenne F, Bartsch P, Foidart JM, Louis R: MMP-2-and MMP-9-linked gelatinolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol 2000; 123:259-267.
17. Cai S, Chen P, Zhu Y: Airway inflammation and macrophage inflammatory protein-1al-pha, gelatinase B level in patients with COPD (in Chinese). Zhonghua Jie He He Hu Xi Za Zhi 2001; 24: 429-432.
18. Xu XM, Sun TY, Lin JB, Zhang HS: The role of matrix metalloproteinases-9 and tissue inhibitor of metalloproteinaes-1 in chronic obstructive pulmonary disease. Zhonghua Yi Xue Za Zhi 2003; 83:1138-1141.
19. Louhelainen N, Stark H, Mazur W, Rytila P, Djukanovic R, Kinnula VL: Elevation of sputum matrix metalloproteinase-9 persists up to 6 months after smoking cessation: a re-sea rch study. BMC Pulm Med 2010; 10: 13.
20. Vernooy JH, Lindeman JH, Jacobs JA, Hane-maaijer R, Wouters EF: Increased activity of matrix metalloproteinase-8 and matrix me-talloproteinase-9 in induced sputum from patients with COPD. Chest 2004; 126:1802-1810. (Pubitemid 39643983)
21. Russell RE, Culpitt SV, DeMatos C, Donnelly L, Smith M, Wiggins J, Barnes PJ: Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2002; 26: 602-609. (Pubitemid 34315869)
22. Li W, Xu Y, Zhang Z: Activity of matrix me-talloproteinase in airway epithelial cells of COPD patients. J Huazhong Univ Sci Tech-nolog Med Sci 2005; 25:151-154.
23. Brajer B, Batura-Gabryel H, Nowicka A, Kuznar-Kaminska B, Szczepanik A: Concentration of matrix metalloproteinase-9 in serum of patients with chronic obstructive pulmonary disease and a degree of airway obstruction and disease progression. J Physiol Pharmacol 2008; 59(suppl 6):145-152.
24. Bolton CE, Stone MD, Edwards PH, Duckers JM, Evans WD, Shale DJ: Circulating matrix metalloproteinase-9 and osteoporosis in patients with chronic obstructive pulmonary disease. Chron Respir Dis 2009; 6: 81-87.
25. Badra G, Lotfy M, El-Refaie A, Obada M, Ab-delmonem E, Kandeel S, Fathy A: Significance of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in chronic hepatitis C patients. Acta Micro-biol Immunol Hung 2010; 57: 29-42.
26. Cataldo D, Munaut C, Noel A, Frankenne F, Bartsch P, Foidart JM, Louis R: Matrix me-talloproteinases and TIMP-1 production by peripheral blood granulocytes from COPD patients and asthmatics. Allergy 2001; 56: 145-151. (Pubitemid 32115765)
27. Barnes PJ, Shapiro SD, Pauwels RA: Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003; 22:672-688. (Pubitemid 37258549)
28. Calverley PM, Walker P: Chronic obstructive pulmonary disease. Lancet 2003; 362: 1053-1061. (Pubitemid 37186885)
29. Higashimoto Y, Iwata T, Okada M, Satoh H, Fukuda K, Tohda Y: Serum biomarkers as pred ic tors of lung f unc tion decline in chronic obstructive pulmonary disease. Respir Med 2009; 103:1231-1238.
30. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM: Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178:332-338.
31. van Diemen CC, Postma DS, Siedlinski M, Blokstra A, Smit HA, Boezen HM: Genetic variation in TIMP1 but not MMPs predict excess FEV1 decline in two general population-based cohorts. Respir Res 2011;12:57.